Welcome to CONCI
For over 45 years, CONCI has remained a staple in the Ohio weight loss community. Why? Because our programs work! A group of licensed medical professionals with specialized education in obesity management design every program....
How to Maintain Weight Loss After GLP-1 Medications
GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) have transformed the landscape of obesity medicine. For many patients, these drugs deliver results that were once only achievable through bariatric surgery, with 15% to 25% of total body...
New World Health Organization Guidelines on the Use of GLP-1 Medications for Obesity
Obesity is a chronic disease and has been identified as such since the World Health Organization (WHO) declared so in 1997. Now, nearly three decades later, the WHO has taken a landmark step forward in addressing this global health challenge by issuing the first-ever...
Medical Weight Loss vs Losing Weight on Your Own
If you've struggled with weight loss on your own, you're not alone. Understanding the difference between medical weight loss and losing weight independently can help you make an informed decision about which approach is right for you. We're more than happy to talk to...
How Does Tirzepatide Work for Weight Loss?
What is Zepbound (Tirzepatide)? Tirzepatide (better known by the brand name Zepbound) is an FDA-approved dual-acting drug for weight loss and obstructive sleep apnea. What's the Difference Between Tirzepatide and Other Weight Loss Drugs? Mounjaro and Zepbound Contain...
GLP-1: The Hormone Transforming Obesity Medicine and Weight Loss
What is a GLP-1 Agonist? GLP-1 (glucagon-like peptide-1) drugs like semaglutide (you may know the brand names Ozempic and Wegovy) are GLP-1 receptor agonists. Glucagon-like peptide-1 is an incretin hormone naturally released in the human body in response to food and...
Combining Meal Replacement Products with Ozempic, Wegovy (Semaglutide), and other GLP-1 Weight Loss Drugs
Obesity has been identified as a chronic disease since the World Health Organization (WHO) declared so in 1997. This was an instrumental milestone in treating and accepting obesity as a chronic condition. Since then, the research has demonstrated the leading cause of...
Ongoing Research: Effects of VLCD and Drug Treatment for Obesity. (Protocol I. Protocol F. CONCI)
Five-year Maintenance Results of an Obesity Drug Following a Very Low Calorie Diet (VLCD) Presented at Obesity Week, 2013
J Loper, R Lutes, T Broyles, R May, E Baltes.
Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-1 Study. American Diabetes Association, 2011.
Smith S, T Church, J Goohas, C Griffin, W Harper, D Krieger, J Loper, Smudahar, C Woodrugg, M Guittalauria, E Henry, D Kim, E Dunayevich.